Collection of circulating progenitor cells after epirubicin, paclitaxel and filgrastim in patients with metastatic breast cancer
1997

Collecting Blood Cells After Chemotherapy for Breast Cancer

Sample size: 10 publication Evidence: moderate

Author Information

Author(s): P Pedrazzoli, C Perotti, GA Da Prada, F Bertolini, N GibeIi, L Torretta, M Battaglia, L Pavesi, P Preti, L Salvaneschi, G Robustelli della Cuna

Primary Institution: IRCCS 'Salvatore Maugeri' Foundation, Rehabilitation Institute of Pavia

Hypothesis

The combination of epirubicin and paclitaxel followed by filgrastim can effectively mobilize circulating progenitor cells in patients with metastatic breast cancer.

Conclusion

The epirubicin-paclitaxel combination is effective in releasing large amounts of progenitor cells into circulation in patients with advanced breast cancer.

Supporting Evidence

  • Six out of ten patients collected more than 2.5 x 10^6 CD34+ cells per kg with a single apheresis.
  • An additional procedure was needed for four patients to reach the required number of progenitor cells.
  • Most patients reached the target of 2.5 x 10^6 CD34+ cells with a single leucapheresis.

Takeaway

Doctors can collect special blood cells from breast cancer patients after giving them certain chemotherapy drugs, which helps in their treatment.

Methodology

Ten patients with metastatic breast cancer received epirubicin and paclitaxel, followed by filgrastim, to mobilize progenitor cells for collection through leucapheresis.

Potential Biases

Potential bias due to the small sample size and lack of control group.

Limitations

The study involved a small sample size and lacked large randomized trials to support the findings.

Participant Demographics

All participants were women with stage IV breast cancer, median age 49 years.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication